COVID-19 vaccines

To Combat COVID-19 Vaccine Hesitancy in Black Community, Twin Sister Doctors Develop Strategy

Retrieved on: 
Friday, July 16, 2021

Delana Wardlaw and Elana McDonald, known as the Twin Sister Doctors, today released a special report offering insightful strategies to combat COVID-19 vaccine hesitancy, particularly in Black communities.

Key Points: 
  • Delana Wardlaw and Elana McDonald, known as the Twin Sister Doctors, today released a special report offering insightful strategies to combat COVID-19 vaccine hesitancy, particularly in Black communities.
  • The Twin Sister Doctors' major goals with this report are to build trust, achieve greater transparency and ultimately attract people to get the shot.
  • The concerns about the Johnson & Johnson vaccine have deepened concerns about vaccine hesitancy.
  • For interviews with The Twin Sister Doctors, contact Neil Foote, [email protected] , 214.448.3765, and to learn more about them, go to TheTwinSisterDocs.com .

Ocugen, Inc. Announces Initiation of Rolling Submission to Health Canada for COVAXIN™

Retrieved on: 
Thursday, July 15, 2021

This follows the release by Bharat Biotech of Phase 3 clinical trial results , which demonstrated efficacy and safety in nearly 25,800 adults.

Key Points: 
  • This follows the release by Bharat Biotech of Phase 3 clinical trial results , which demonstrated efficacy and safety in nearly 25,800 adults.
  • Often referred to as a rolling review, this allows Health Canada to start its review right away, as information continues to come in, to accelerate the overall review process.
  • Ocugen initiated the rolling submission through its affiliate, Vaccigen, Ltd. Health Canada will make a decision upon review of the evidence submitted that supports its safety, efficacy and quality.
  • Based on the more than 30 million doses supplied in India and other countries, COVAXIN has an excellent safety record.

Novel Saliva Assay by Accure Health Tracks COVID-19 Vaccine Response in Proof-of-Concept Study

Retrieved on: 
Thursday, July 15, 2021

Accure Health , a developer of rapid digital diagnostics, today announced the online publication of preliminary data showing that its novel saliva assay can assess individual immune response to COVID-19 vaccines, monitor neutralizing antibody levels over time, and model immune protection against SARS-Cov-2 variants.

Key Points: 
  • Accure Health , a developer of rapid digital diagnostics, today announced the online publication of preliminary data showing that its novel saliva assay can assess individual immune response to COVID-19 vaccines, monitor neutralizing antibody levels over time, and model immune protection against SARS-Cov-2 variants.
  • In a pilot study involving 111 participants, Accure Health demonstrated the potential of its TiMES digital platform and TiMES-Now assay in monitoring the neutralizing antibody levels against SARS-CoV-2 in saliva samples.
  • Critical questions such as the durability of COVID-19 immunity or the clinical efficacy of vaccines require large datasets to generate meaningful insights.
  • Accure Health has active collaborations with the Massachusetts General Hospital, and PATH, among others.

Cigna International finds community spirit and duty to society top driver of COVID-19 vaccine uptake

Retrieved on: 
Thursday, July 15, 2021

The research shows vaccine hesitancy, or a "wait and see" approach to vaccination, has dropped significantly over the past three months.

Key Points: 
  • The research shows vaccine hesitancy, or a "wait and see" approach to vaccination, has dropped significantly over the past three months.
  • The first wave of research in March showed 50% of respondents waiting to get a vaccine.
  • Jason Sadler, president, Cigna InternationalMarketssaid: "The findings from our third COVID-19 Vaccine Perception Study highlight some incredible progress in global vaccination programs.
  • Globally, 9% of those yet to receive a vaccine were adamant that nothing could persuade them to take the COVID-19 vaccine.

Researchers to investigate vaccine uptake, efficacy and side effects in vulnerable urban populations

Retrieved on: 
Wednesday, July 14, 2021

The Government of Canada, through the COVID-19 Immunity Task Force (CITF) and the Vaccine Surveillance Reference Group (VSRG), is investing approximately $770,000 in a new study that will investigate the uptake, effectiveness, and side effects of COVID-19 vaccines among members of vulnerable urban populations in Canada.

Key Points: 
  • The Government of Canada, through the COVID-19 Immunity Task Force (CITF) and the Vaccine Surveillance Reference Group (VSRG), is investing approximately $770,000 in a new study that will investigate the uptake, effectiveness, and side effects of COVID-19 vaccines among members of vulnerable urban populations in Canada.
  • Researchers will recruit more than 250 people who use drugs from three community-recruited cohorts in Vancouver, British Columbia.
  • Following their first visit, researchers aim to assess vaccine uptake, adherence to vaccination protocols, as well as monitor and investigate potential side effects of the vaccines.
  • Researchers will also analyze the effectiveness of the SARS-CoV-2 vaccines and compare their effectiveness among subgroups of vulnerable populations.

BurstIQ & FlowMetric Life Sciences Partner to develop VaxEffect™, a diagnostic Platform for COVID-19 Immune Response Testing

Retrieved on: 
Wednesday, July 14, 2021

DENVER, July 14, 2021 /PRNewswire/ -- BurstIQ , the leading provider of blockchain enabled data exchange solutions, announced today that longtime partner FlowMetric Life Sciences , launched their novel vaccine immune response test, VaxEffect.

Key Points: 
  • DENVER, July 14, 2021 /PRNewswire/ -- BurstIQ , the leading provider of blockchain enabled data exchange solutions, announced today that longtime partner FlowMetric Life Sciences , launched their novel vaccine immune response test, VaxEffect.
  • "The goal of the collaboration with BurstIQ was to bring the VaxEffect COVID-19 vaccine immune response test and powerful personalized results to health care providers and their patients.
  • BurstIQ is the leading provider of blockchain-enabled data solutions for the identity, healthcare and life sciences industries.
  • The experienced team of scientists at FlowMetric Diagnostics, a division of FlowMetric Life Sciences Inc. (FlowMetric), has introduced VaxEffect, the world's first COVID-19 vaccine immune response test built upon superior Flow Cytometry technology.

Google Trends, the COVID-19 Vaccine, and Infertility Misinformation

Retrieved on: 
Tuesday, July 13, 2021

It is important to note that the petitioners acknowledged the absence of any evidence associating female infertility risks with COVID-19 vaccines.

Key Points: 
  • It is important to note that the petitioners acknowledged the absence of any evidence associating female infertility risks with COVID-19 vaccines.
  • Anti-vaccine advocates seized on this concern to create a misinformation claim misrepresenting the EMA petition, and the public turned to Google to understand if the information was legitimate.
  • At peak interest, the Google search terms "infertility," "infertility AND vaccine," and "infertility AND COVID vaccine" experienced increases of 119.9%, 11,251%, and 34,900%, respectively, when compared with forecasted values.
  • "In the battle to fight misinformation, Google Trends can be an effective tool to help physicians recognize and proactively address false claims with patients."

FlowMetric Life Sciences Inc. Introduces the Breakthrough VaxEffect™ COVID-19 Vaccine Immune Response Test

Retrieved on: 
Tuesday, July 13, 2021

DOYLESTOWN, Pa., July 13, 2021 /PRNewswire/ -- FlowMetric Life Sciences Inc., a globally recognized life sciences company, announces the launch of VaxEffect COVID-19 Vaccine Immune Response Test, a unique and powerful platform exclusively created to quantitatively assess and track, now and over time, an individual's immune response to any of the COVID-19 vaccines currently available in the United States.

Key Points: 
  • DOYLESTOWN, Pa., July 13, 2021 /PRNewswire/ -- FlowMetric Life Sciences Inc., a globally recognized life sciences company, announces the launch of VaxEffect COVID-19 Vaccine Immune Response Test, a unique and powerful platform exclusively created to quantitatively assess and track, now and over time, an individual's immune response to any of the COVID-19 vaccines currently available in the United States.
  • "The VaxEffect test will be especially important for patients with immune compromised conditions such as those fighting cancer, diabetes, auto-immune disorders, or those that are immunosuppressed due to organ transplantation, who may have not generated a strong immune response to the vaccine" noted Grant Morgan, Ph.D., General Manager of VaxEffect and EVP of FlowMetric Life Sciences Inc.
  • The VaxEffect COVID-19 Vaccine Immune Response Test is a Laboratory Developed Test (LDT) that has been developed and validated by talented scientists in our FlowMetric Diagnostics' CLIA-certified and CAP-accredited High Complexity Laboratory.
  • FlowMetric Diagnostics is a division of FlowMetric Life Sciences, Inc., a globally recognized Contract Research Organization.

ARCA biopharma Provides Update on ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 as a Potential Treatment for COVID-19

Retrieved on: 
Tuesday, July 13, 2021

The Company also updated its guidance and now anticipates topline data from this international Phase 2b clinical trial in the fourth quarter of 2021.

Key Points: 
  • The Company also updated its guidance and now anticipates topline data from this international Phase 2b clinical trial in the fourth quarter of 2021.
  • ASPEN-COVID-19 is a Phase 2b randomized, multi-center, international clinical trial evaluating two dose regimens of rNAPc2 versus heparin in approximately 160 hospitalized SARS-CoV-2 positive patients that also have an elevated D-dimer level.
  • Other objectives of Phase 2b are to assess safety and determine the optimal dose regimen of rNAPc2 for Phase 3.
  • ARCA is developing rNAPc2 as a potential treatment for diseases caused by RNA viruses, initially focusing on COVID-19.

RDIF and Serum Institute of India, the world's largest vaccine manufacturer by volume, to start production of Sputnik vaccine at Company's facilities in September

Retrieved on: 
Tuesday, July 13, 2021

SII is the world's largest company in terms of COVID vaccines production with over 500 million doses manufactured.

Key Points: 
  • SII is the world's largest company in terms of COVID vaccines production with over 500 million doses manufactured.
  • The first batch of Sputnik vaccine is expected to be produced at SII's facilities in September.
  • Kirill Dmitriev, CEO of the Russian Direct Investment Fund, commented:
    "RDIF is delighted to cooperate with Serum Institute of India, the world's largest vaccine manufacturer.
  • Adar Poonawalla, CEO of Serum Institute of India,commented:
    "I am delighted to partner with RDIF to manufacture the Sputnik vaccine.